StreetAlpha.app
Home › Stocks › COLL

Collegium Pharmaceutical, Inc (COLL)

Healthcare
$24.72
▼ −1.94%
LAST CLOSE · NOV 20

Collegium Pharmaceutical sells prescription medicines for ADHD and pain in the United States. It last closed at $24.72 on Nov 20, down 1.94% on the day. The next earnings report for COLL is expected around Thu, Feb 25, 2027. For the quarter ended Sep 2026, COLL reported EPS of $0.60 on revenue of $216.3M, with revenue up 3.3% from a year ago. Over its last 8 reports the stock moved an average of 8.5% the session after earnings. Over the last 12 months COLL insiders bought $0 of stock on the open market and sold $4.4M, according to SEC Form 4 filings.

AI Auto Pilots
Is COLL in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold COLL.

Key Stats

Last 12 months
Results
Revenue
$815.2M
+7.7% vs a year ago
Net income
$38.2M
−34.7% vs a year ago
EPS (diluted)
$1.09
−33.1% vs a year ago
Free cash flow
$336.3M
41.3% margin
Valuation
Market cap
$768.2M
31.1M shares
P/E
22.7
Price over 12 month EPS
Price to sales
0.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$144.8M
At Sep 30
Debt
$239.0M
At Sep 30
Shareholder equity
$296.4M
Buybacks
$50.0M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $276.9M$276.9MFY2021FY2022: $463.9M$463.9MFY2022FY2023: $566.8M$566.8MFY2023FY2024: $631.4M$631.4MFY2024FY2025: $780.6M$780.6MFY2025

From COLL's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Feb 25
Estimated date · Time not announced
Reported EPS
$0.60
Quarter ended Sep 2026
Year ago EPS
$0.84
−28.6% on a GAAP basis
Revenue
$216.3M
+3.3% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.36Dec '24Mar 2025: $0.07Mar '25Jun 2025: $0.34Jun '25Sep 2025: $0.84Sep '25Dec 2025: $0.46Dec '25Mar 2026: $0.40Mar '26Jun 2026: -$0.46Jun '26Sep 2026: $0.60Sep '26Latest $0.60
Revenue by quarter
Dec 2024: $181.9MDec '24Mar 2025: $177.8MMar '25Jun 2025: $188.0MJun '25Sep 2025: $209.4MSep '25Dec 2025: $205.4MDec '25Mar 2026: $193.5MMar '26Jun 2026: $199.9MJun '26Sep 2026: $216.3MSep '26Latest $216.3M
How COLL moved after its last 8 reports
Average move the session after a report ±8.5%
Nov 5, 2026Time not announced+6.3%
Aug 6, 2026Time not announced−18.6%
May 7, 2026Time not announced+7.7%
Feb 26, 2026Time not announced−3.3%
Nov 6, 2025Time not announced+13.4%
Aug 7, 2025Time not announced+10.7%
May 8, 2025After the close+5.9%
Feb 27, 2025After the close+2.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on COLLStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on COLL
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on COLL

Technical Analysis

COLL · as of the Nov 20 close · updated each morning
Bounce inside a longer downtrend

The stock is 1% above its 20 day and 6% above its 50 day average. It is 28% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 54). The nearest support is the 20 day average at $24.44, and the nearest resistance the Pivot at $24.93.

Short trendBullish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityNormal, 3.7%/day
Key levels
$50.7952 week high+105.5%
$31.61200 day average+27.9%
$27.03100 day average+9.3%
$26.39Swing high (Nov 5)+6.8%
$25.22Pivot R1+2.0%
$24.93Pivot+0.8%
$24.72Last close
$24.4420 day average−1.1%
$24.43Pivot S1−1.2%
$23.2550 day average−5.9%
$22.15Swing low (Oct 23)−10.4%
$21.4352 week low−13.3%
Indicators
RSI (14)53.68Middle of its rangeNeutral
MACD0.54Above its signal lineBullish
Stochastic63.9Middle of its rangeNeutral
ADX (14)30.3Trending up
Williams %R-56.1Oversold below −80, overbought above −20Neutral
CCI (20)47.1Oversold below −100, overbought above 100Neutral
Rate of change+2.1%Change over 10 sessionsBullish
ATR (14)$0.91Typical daily range, 3.7% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Below
MA 200Below
What happened before, for COLL

What happened before

See how COLL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow COLL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How COLL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for COLLHow many large options trades hit COLL, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

COLL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼120 buying vs 164 selling
  • ▼Held by funds -14.6 pts
  • ▼Funds holding -42
  • ▲Superinvestors: 4 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding240282−14.9%
In funds' top 1010–
Held by funds120.4%135.0%−14.6 pts
New / increased35 / 8543 / 122−27.3%
Reduced / sold out87 / 7782 / 31+45.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See COLL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

COLL Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$4.4M9 sales · 6 insiders
82% of the selling was under pre-arranged trading plans.
2025-12 sold $1.0M2026-03 sold $2.7M2026-05 sold $629KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
May 18John Gordon FreundDirectorSale20$34.05$681
May 15John Gordon FreundDirectorSale4,127$34.54$143K
May 13Nancy LurkerDirectorSale4,500$35.97$162K
May 11Garen G BohlinDirectorSale8,700$37.18$323K
Mar 18David DieterEVP & General CounselSale plan13,976$34.92$488K
Mar 9David DieterEVP & General CounselSale plan6,224$36.65$228K
Every insider buy and sale for COLL over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See COLL insider trades →

From SEC Form 4 filings by COLL's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether COLL is in one of them and how their past COLL trades turned out.

COLL in the AI portfolios
Loading…

COLL News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered COLL in an article yet. Here's the latest on the wider market.

COLL in the news

About Collegium Pharmaceutical

Collegium Pharmaceutical is a biopharmaceutical company based in Stoughton, Massachusetts. It sells prescription medicines in the United States for attention deficit hyperactivity disorder and for moderate to severe pain. Its products include Jornay PM for ADHD, Belbuca, Xtampza ER and the Nucynta products for pain, and Symproic for constipation caused by opioid use. Its customers are patients who receive these medicines through prescriptions written by doctors.

Headquarters
Stoughton, MA